Skip to main content
Oria Health
Updated October 2026
growth hormoneGHRHanti-aging

Sermorelin

GHRH(1–29) analog · pituitary GH secretagogue

A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), FDA approved for diagnosing and treating pediatric growth hormone deficiency. Preserves the body's natural pulsatile GH release pattern for optimized GH levels with fewer side effects than direct HGH injection.

Sermorelin
Evidence Grade
A-
Trial Stage
Approved (pediatric)
A-
Evidence Grade
FDA Status
Discontinued
Geref (approved 1997)
Amino Acids
29
first 29 aa of GHRH
GH Increase
Significant
in GHD children & adults
Discontinued
2008
commercial reasons, not safety
Side Effect Profile
Low
Moderate
Serious
Injection site reactions15%
Flushing10%
Headache8%
Dizziness5%
Joint pain3%
Nausea3%
Research Timeline
1980s
GHRH analogue developed
1990
Phase III trials completed
1997
FDA approves Geref
2008
Manufacturer discontinues
2020s
Compounding pharmacy use
Research In Progress·Full clinical analysis pending. Community notes and FAQ available below.

Sermorelin is a 29-amino-acid peptide identical to the active fragment of the growth hormone-releasing hormone (GHRH) your hypothalamus already produces. The full GHRH molecule is 44 amino acids, but research established that the first 29 carry all the biological activity. The FDA approved sermorelin (brand name Geref) in 1997 for diagnosing and treating growth hormone deficiency in children. Off-label adult use for GH optimization became widespread in the 2000s as a safer alternative to direct HGH injection, and the peptide became one of the most widely prescribed compounds in anti-aging medicine following patent expiration.

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering GH release in a pulsatile pattern that mirrors the body's natural rhythm — primarily during deep sleep and after exercise. This is the key distinction from direct HGH injection. Exogenous HGH bypasses the body's regulatory feedback loops entirely, producing constant elevated GH levels with risk of insulin resistance, joint pain, and fluid retention. Sermorelin works through the pituitary's existing regulatory architecture. After GH release, natural feedback mechanisms (somatostatin, IGF-1) modulate further secretion. The downstream effects include increased IGF-1 production, improved protein synthesis, enhanced lipolysis, better sleep architecture, and improved tissue repair.

Sleep improvement is consistently the first benefit users notice, often within the first week. Body composition changes — reduced fat, preserved lean muscle — are slower but sustained over 3 to 6 months. Exercise recovery improves as GH-driven tissue repair accelerates. The overall effect profile is the same as optimized GH levels, arrived at through a mechanism the body is already designed to use.

Community Experiences

"The first time in years I slept through the night without waking up at 3 AM. Sleep quality improved within the first week. That alone is worth it." — r/Peptides

"The body composition changes are slow — you're not going to look different in a month. But at 12 weeks the difference in how you feel and how you look is real." — r/Peptides

"Compared to injecting actual HGH, sermorelin is just smoother. You're not overriding your body, you're asking it nicely. The side effect profile is completely different." — r/Biohackers

Sermorelin research

Growth hormone secretagogue research for optimized GH release

Frequently Asked Questions

Is sermorelin FDA approved? Yes. Sermorelin was FDA approved in 1997 for diagnosing and treating growth hormone deficiency in children. Adult use for GH optimization is off-label and widely practiced in anti-aging medicine.

How does sermorelin differ from HGH? Sermorelin stimulates the pituitary to release GH in natural pulses. Direct HGH injection bypasses regulatory feedback, providing constant elevated levels with a higher risk of side effects including insulin resistance and joint pain.

What is the typical research dose? Common protocols use 100 to 300 mcg administered subcutaneously at bedtime, aligned with the body's natural GH release pattern during deep sleep.

How long before results appear? Sleep improvements often appear within the first week. Body composition and recovery benefits typically take 8 to 12 weeks of consistent use.

Stacking Suggestions

  • Ipamorelin for a synergistic GH release stack — sermorelin via GHRH receptors, ipamorelin via ghrelin receptors, combined GH output
  • CJC-1295 for extended GHRH receptor stimulation with a longer half-life
  • BPC-157 for tissue repair support while sermorelin optimizes GH levels
  • GHK-Cu for skin health benefits that complement sermorelin's GH-mediated skin improvements
  • MOTS-c for metabolic support alongside GH optimization

Get Your BioStack →

Verified Literature & Trial Registry · NCBI PubMed & ClinicalTrials.gov

Sermorelin: Indexed Studies & Clinical Trials

334 PubMed Publications Indexed

Evidence & Scope Notice (R06): The records below are retrieved directly from NCBI PubMed and ClinicalTrials.gov. Preclinical (rodent/in vitro) studies do not establish human safety or efficacy. This index is for educational research literacy only and is never medical advice.

Registered Human Clinical Trials (ClinicalTrials.gov)

NCT03031535 ↗PHASE1COMPLETED

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Conditions: Healthy Volunteer Study

Primary Endpoint: Percentage of subjects reporting adverse events (AEs)/serious adverse events (SAEs).

Enrollment: N=32View NCT Record →
NCT01263717 ↗NACOMPLETEDResults Posted

Effects of Growth Hormone Releasing Hormone in HIV

Conditions: HIV, HIV Lipodystrophy

Primary Endpoint: Liver Fat

Enrollment: N=54View NCT Record →
NCT00257712 ↗PHASE2COMPLETED

SMART: Somatotrophics, Memory, and Aging Research Trial

Conditions: Aging, Mild Cognitive Impairment

Primary Endpoint: Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.

Enrollment: N=151View NCT Record →
NCT00807365 ↗PHASE2TERMINATEDResults Posted

Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

Conditions: Elderly

Primary Endpoint: Change in Lean Body Mas

Enrollment: N=5View NCT Record →
NCT00791843 ↗PHASE2COMPLETEDResults Posted

The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

Conditions: Congestive Heart Failure

Primary Endpoint: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment, Physical Exam

Enrollment: N=3View NCT Record →

Selected Peer-Reviewed PubMed Literature

PMID: 18046908 ↗2006· Clinical interventions in aging

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Walker RF · DOI: 10.2147/ciia.2006.1.4.307

PMID: 34665524 ↗2021 Nov· Drug testing and analysis

Advances in the detection of growth hormone releasing hormone synthetic analogs

Memdouh S, Gavrilović I, Ng K et al. · DOI: 10.1002/dta.3183

PMID: 18031173 ↗1999 Aug· BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

Prakash A, Goa KL · DOI: 10.2165/00063030-199912020-00007

PMID: 33842627 ↗2021 Mar· Annals of translational medicine

A potentially effective drug for patients with recurrent glioma: sermorelin

Chang Y, Huang R, Zhai Y et al. · DOI: 10.21037/atm-20-6561

PMID: 41880199 ↗2026 Jul· The Journal of sports medicine and physical fitness

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review

Coutinho LFD, DE Oliveira Neves LF, Camilo RP · DOI: 10.23736/S0022-4707.26.17773-1

PMID: 32257855 ↗2020 Mar· Translational andrology and urology

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males

Sinha DK, Balasubramanian A, Tatem AJ et al. · DOI: 10.21037/tau.2019.11.30